The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Autor: Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly, Devlin, Sean M, Pajarillo, Raymone, Slingerland, John B, Beghi, Silvia, Herrera, Pamela S, Giardina, Paul A, Clurman, Annelie, Dwomoh, Emmanuel A, Armijo, Gabriel K, Gomes, Antonio L.C., Littmann, Eric R, Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H, Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel D, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred L, Gier, Shannon H, Nasta, Sunita, Landsburg, Daniel J, Gerson, James N, Svoboda, Jakub, Cross, Justin, Chong, Elise A, Giralt, Sergio A, Gill, Saar, Rivière, Isabelle, Porter, David L, Schuster, Stephen J, Sadelain, Michel, Frey, Noelle V, Brentjens, Renier J, June, Carl H, Pamer, Eric G, Peled, Jonathan U, Ruella, Marco, van den Brink, Marcel, Facciabene, Andrea
Zdroj: Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p253-253, 1p
Abstrakt: Introduction: Cellular immunotherapy with CD19-targeted chimeric antigen receptor (CAR) T cells has provided new therapeutic options for patients with high-risk hematologic malignancies. Following this therapy, patients may experience disease relapse or CAR-mediated toxicity due to cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Recent studies have confirmed that the intestinal microbiome can modulate the anti-tumor immune response to chemotherapy, immune checkpoint blockade, graft-versus-host disease after allogeneic hematopoietic cell transplantation, and adoptive cellular therapy. The contribution of the intestinal microbiome on the function of CAR T cells in vivoboth with respect to their anti-tumor function and their propensity to induce toxicities is not known. Hence, in a multi-center study we analyzed the association between clinical outcomes and (1) antibiotic exposure prior to CAR T cell infusion and (2) the composition and diversity of the fecal microbiome.
Databáze: Supplemental Index